Imagion Biosystems Ltd. (AU:IBX)
ASX:IBX
Want to see AU:IBX full AI Analyst Report?
Top Page
Imagion Biosystems Ltd.
(Sydney:IBX)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.01
â–¼(-56.67% Downside)
Action:Reiterated
Date:05/27/26
The score is held down primarily by very weak financial performance (zero revenue in 2025, persistent losses, ongoing cash burn, and negative equity). Technicals add additional pressure with a downtrend versus key moving averages and negative MACD, while valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Proprietary Technology
Imagion’s MagSense platform is a differentiated diagnostic technology built around magnetic nanoparticles and imaging for cancer detection. A proprietary, clinically oriented platform can provide durable competitive advantage if clinical validation and regulatory approvals progress, underpinning long-term product moat and commercial potential.
Negative Factors
Zero Revenue in 2025
Revenue falling to zero in 2025 shows the company has not yet achieved commercial traction or recurring sales, meaning value relies entirely on future clinical and regulatory progress. Persistent losses without revenue create long-term funding dependency and execution risk for commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Technology
Imagion’s MagSense platform is a differentiated diagnostic technology built around magnetic nanoparticles and imaging for cancer detection. A proprietary, clinically oriented platform can provide durable competitive advantage if clinical validation and regulatory approvals progress, underpinning long-term product moat and commercial potential.
Read all positive factors
Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$6.87M
Dividend YieldN/A
Average Volume (3M)16.05M
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth-100.00%
EPS Growth68.62%
CountryAU
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding490,590,240
10 Day Avg. Volume7,347,790
30 Day Avg. Volume16,053,124
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Imagion Biosystems Ltd. Business Overview & Revenue Model
Company Description
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superpara...
How the Company Makes Money
null...
Imagion Biosystems Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 2.67M | 1.08M | 473.43K | 232.87K |
| Gross Profit | -8.81K | 2.26M | -279.83K | -3.14M | -2.47M |
| EBITDA | -3.58M | -700.09K | -10.30M | -11.03M | -5.62M |
| Net Income | -4.31M | -2.07M | -12.47M | -9.81M | -6.02M |
Balance Sheet | |||||
| Total Assets | 2.04M | 2.80M | 4.59M | 9.98M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 1.85M | 2.67M | 227.08K | 4.45M | 13.39M |
| Total Debt | 2.56M | 2.85M | 6.04M | 4.60M | 46.02K |
| Total Liabilities | 4.21M | 5.09M | 8.37M | 5.30M | 809.88K |
| Stockholders Equity | -2.16M | -2.28M | -3.79M | 4.68M | 13.31M |
Cash Flow | |||||
| Free Cash Flow | -4.04M | -1.27M | -8.51M | -9.21M | -5.29M |
| Operating Cash Flow | -4.04M | -1.27M | -8.32M | -8.70M | -5.07M |
| Investing Cash Flow | 0.00 | 83.74K | -190.38K | -468.73K | -310.09K |
| Financing Cash Flow | 3.24M | 3.61M | 4.29M | -962.06K | 5.15M |
Imagion Biosystems Ltd. Technical Analysis
Positive
0.03
Price Trends
0.02
Positive
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
55.36
Neutral
141.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IBX, the sentiment is Positive. The current price of 0.03 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.36 is Neutral, neither overbought nor oversold. The STOCH value of 141.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IBX.
Imagion Biosystems Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$52.23M | 24.58 | 72.82% | ― | 22.56% | 19.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$106.86M | -6.82 | -164.12% | ― | -14.85% | -41.04% | |
41 Neutral | AU$6.87M | -1.35 | 142.99% | ― | -100.00% | 68.62% | |
40 Underperform | AU$28.20M | -3.99 | -164.22% | ― | ― | 26.04% | |
38 Underperform | AU$45.05M | -5.54 | -37.14% | ― | 4.66% | 12.39% |
* Healthcare Sector Average
AU:IBX
Imagion Biosystems Ltd.
0.02
<0.01
33.33%
AU:BDX
BCAL Diagnostics Limited
0.08
0.00
0.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.12
0.09
283.33%
AU:CTE
Cryosite Limited
1.10
0.35
46.67%
AU:IIQ
Inoviq Ltd
0.33
-0.24
-41.96%
Imagion Biosystems Ltd. Corporate Events
Imagion Biosystems AGM Backs Board, Incentive Plan and Capital Flexibility
May 26, 2026
Imagion Biosystems reported the results of its annual general meeting held on 26 May 2026, with all resolutions put to shareholders passed by the required majorities. The adoption of the remuneration report and the election of directors, including...
Imagion Biosystems outlines molecular MRI strategy and investor risk caveats
May 26, 2026
Imagion Biosystems has released an investor presentation outlining its focus on molecular MRI as a next generation imaging platform for early cancer detection. The deck is presented as informational only, with extensive legal and risk disclosures ...
Imagion Biosystems advances MagSense cancer imaging with first FDA IND filing
May 26, 2026
Imagion Biosystems used its 2025 Annual General Meeting to underline progress in developing its MagSense molecular imaging platform, which aims to offer safer, more targeted MRI contrast agents than conventional media and a competitive alternative...
Imagion Biosystems director adjusts holding of performance options
May 8, 2026
Imagion Biosystems has reported a change in the equity interests held by director Robert Romeo Proulx, as disclosed in an updated notice to the ASX. The filing details the disposal of 50,000 unlisted performance options at no consideration, adjust...
Imagion Biosystems Options Lapse, Trimming Potential Dilution
May 4, 2026
Imagion Biosystems Limited has reported the cessation of a tranche of listed options on the ASX, identified by the code IBXAAA, which expired unexercised on 1 May 2026. The expiry of 68,750 options with an exercise price of $1.12 slightly reduces ...
Imagion Biosystems moves 2026 AGM online and digitises shareholder communications
Apr 24, 2026
Imagion Biosystems Limited has convened its 2026 Annual General Meeting, to be held virtually via webinar on 26 May at 10:00am AEST, reflecting ongoing adoption of online formats for shareholder meetings. The company has shifted to electronic dist...
Imagion Biosystems Issues New Unquoted Convertible Notes and Options
Apr 23, 2026
Imagion Biosystems has notified the ASX of the issue of 330,000 unquoted convertible notes and more than 10.6 million unquoted options, both dated 23 April 2026. The options, which expire in April 2029 with an exercise price of $0.0297, and the co...
Imagion Biosystems Secures Additional Convertible Note Funding and Amends Terms
Apr 23, 2026
Imagion Biosystems has adjusted its funding structure under an existing Convertible Securities Agreement, which provides up to $15 million from U.S.-based investors Mercer Street Global Opportunity Fund and affiliated C/M Capital Partners. The com...
Imagion Biosystems advances MagSense breast cancer trial toward U.S. Phase 2 start
Apr 23, 2026
Imagion Biosystems has submitted its first Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 2 clinical trial of its MagSense imaging agent in HER2-positive breast cancer patients. The company has completed ...
Imagion Biosystems plans capital raise via convertible notes and options issue
Apr 16, 2026
Imagion Biosystems has notified the ASX of a proposed issue of new securities as part of a placement or similar capital-raising transaction, with an intended issue date of April 23, 2026. The company plans to issue up to 330,000 convertible notes ...
Imagion Biosystems Secures Extra Funding and Extends Note Maturities
Apr 8, 2026
Imagion Biosystems has secured an additional US$300,000 in short‑term funding from a fund managed by U.S.‑based C/M Capital Partners, under its existing convertible securities framework originally established with Mercer Street Global ...
Imagion Biosystems Sets 2026 AGM Date and Director Nomination Deadline
Apr 7, 2026
Imagion Biosystems has scheduled its 2026 Annual General Meeting for 26 May 2026 in Melbourne and has set 5pm AEST on 14 April 2026 as the deadline for shareholders to submit nominations for candidates to stand for election as directors. The forth...
Imagion Biosystems Reports Expiry of Unexercised Options
Apr 2, 2026
Imagion Biosystems Limited has notified the ASX of the cessation of a class of options, with 353,474 IBXAAR options expiring on March 23, 2026, without being exercised or converted. The expiry of these options slightly reduces the company’s ...
Imagion Biosystems addresses late ASX filing on convertible note repayment
Apr 2, 2026
Imagion Biosystems has advised that it recently lodged an Appendix 3H with the ASX relating to the part repayment of convertible notes held by Mercer Street Global Opportunity Fund, after the filing was submitted later than required due to an admi...
Imagion Biosystems Redeems 300,000 Convertible Notes Without Conversion
Apr 2, 2026
Imagion Biosystems has reported a change to its capital structure following the cessation of a tranche of its convertible securities. The company notified the ASX that 300,000 IBXAAQ convertible notes have been repaid or redeemed without conversio...
Imagion Biosystems posts wider 2025 loss with no revenue or dividends
Feb 27, 2026
Imagion Biosystems reported no revenue from ordinary activities for the year ended 31 December 2025, with its net loss after tax widening 108.5% to $4.31 million compared with the prior year. The company’s net tangible assets per share impro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.